Differentiation between hepatic angiomyolipoma and hepatocellular carcinoma in individuals who are not at-risk for hepatocellular carcinoma

•Differentiating hepatic AML from HCC is clinically important.•We developed and AML-HCC score based on sex and imaging findings of AML and HCC.•Our AML-HCC score showed good performance in differentiating AML from HCC. To develop a practical methodfor differentiating hepatocellular carcinoma (HCC) f...

Full description

Saved in:
Bibliographic Details
Published in:European journal of radiology 2023-09, Vol.166, p.110957-110957, Article 110957
Main Authors: Park, Sungtae, Kim, Myeong-Jin, Han, Kyunghwa, Park, Jae Hyon, Han, Dai Hoon, Park, Young Nyun, Kim, Jaehyo, Rhee, Hyungjin
Format: Article
Language:English
Subjects:
Angiomyolipoma
Gadoxetic acid
Hepatocellular carcinoma
Magnetic resonance imaging
Necrosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Differentiating hepatic AML from HCC is clinically important.•We developed and AML-HCC score based on sex and imaging findings of AML and HCC.•Our AML-HCC score showed good performance in differentiating AML from HCC. To develop a practical methodfor differentiating hepatocellular carcinoma (HCC) from angiomyolipoma (AML) in individuals who are not at-risk for HCC. We retrospectively enrolled consecutive patients who underwent gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) and pathological confirmation between January 2008 and April 2022. Patients who underwent prior treatment, those with multiple lesions, or those at-risk for HCC were excluded. The training cohort included patients with pathological confirmation between 2008 and 2019, whereas the validation cohort included the remaining cases. Independent reviews of the MRI were performed by two reviewers. Using the clinical and MRI findings, we developed AML-HCC score using Firth’s logistic regression in the training cohort, and the diagnostic performance was validated in the validation cohort. Of the 206 patients, 156 were assigned to the training cohort (25 and 131 patients with AML and HCC, respectively) and 50 were assigned to the validation cohort (4 and 46 patients with AML and HCC, respectively). The AML-HCC score was defined as the sum of female (score 1), early draining vein (score 2), T2 homogeneity (score 1), necrosis or severe ischaemia (score −2), and HBP hyperintensity to spleen (score −1). When the AML-HCC score was ≥1, the sensitivity and specificity were 80% and 95% for the training cohort and 100% and 80% for the validation cohort, respectively. We developed and validated an AML-HCC score to differentiate between AML and HCC in individuals who are not at-risk for HCC, and our model demonstrated good diagnostic performance.
ISSN:0720-048X
1872-7727
DOI:10.1016/j.ejrad.2023.110957